Search
Rimiducid
go.drugbank.com/drugs/DB04974InvestigationalWhen administered via chemically-inducible dimerization (CID) technologies, rimiducid binds to switch proteins and dimerizes them, triggering downstream signaling cascade. … It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function.
Aminocaproic acid
go.drugbank.com/drugs/DB00513ApprovedInvestigationalAn antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
Rilematovir
go.drugbank.com/drugs/DB15672InvestigationalRilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With
Mito-4509
go.drugbank.com/drugs/DB05846ExperimentalIt is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders.
NBI-6024
go.drugbank.com/drugs/DB05819InvestigationalNBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.
Brodimoprim-4,6-Dicarboxylate
go.drugbank.com/drugs/DB02809ExperimentalThis compound belongs to the anisoles. These are organic compounds contaiing a methoxybenzene or a derivative thereof. This medication is known to target the protein dihydrofolate reductase.
Dichlorophen
go.drugbank.com/drugs/DB11396InvestigationalVet approvedDichlorophen is an antimicrobial agent shown to exert activity against cestodes, protozoa, fungi, and bacteria. … It is often combined with toluene to remove parasites including ascarids, tapeworm, and hookworm from dogs and cats.
Clinafloxacin
go.drugbank.com/drugs/DB14025ExperimentalIt has been proven to present good antibiotic properties. However, its approval and release have been halted due to the presence of serious side effects.
VXA-CoV2-1
go.drugbank.com/drugs/DB16433InvestigationalThis oral vaccine aims to induce immunogenicity through induction of potent serum neutralizing antibodies to the SARS-CoV-2 spike protein, induction of mucosal immune responses, and induction of T-cell … responses to both vaccine antigens of the SARS-CoV-2 nucleocapsid and spike proteins[L30498].